10-Q: GB Sciences Q3 2025: Revenue Growth Amidst Going Concern

GB Sciences reported its first revenue from a new licensing agreement in Q3 2025, alongside reduced operating losses, but continues to face substantial doubt about its ability to continue as a going concern due to significant accumulated deficit and liquidity challenges.

Summary

• GB Sciences, a plant-inspired biopharmaceutical R&D company, reported its first revenue of $97,235 for the three and nine months ended December 31, 2024, stemming from a new licensing agreement with EndoPure Life Sciences, LLC.
• The company significantly reduced its general and administrative expenses to $163,826 for the three months and $575,753 for the nine months ended December 31, 2024, down from $234,007 and $1,050,621 respectively in the prior year periods.
• Net loss improved to $(100,355) for the three months and $(575,899) for the nine months ended December 31, 2024, compared to $(187,276) and $(894,630) in the corresponding prior year periods.
• Despite operational improvements, the company's accumulated deficit increased to $(110,642,891) at December 31, 2024, from $(110,066,992) at March 31, 2024.
• Cash and cash equivalents stood at $3,016 at December 31, 2024, a decrease from $11,991 at March 31, 2024.
• The working capital deficit worsened to $(5,323,014) at December 31, 2024, from $(4,992,115) at March 31, 2024.
• Several convertible notes and a 0% note payable are currently in default, with total notes and convertible notes payable increasing to $1,994,307 at December 31, 2024, from $1,759,307 at March 31, 2024.
• The company's intellectual property portfolio includes 8 U.S. and 12 foreign issued patents, 2 foreign allowed patents, and 15 U.S. and 41 foreign patent-pending applications, covering over 65 medical conditions.
• Preclinical studies showed positive results for Parkinson's disease, chronic pain, anxiety/depression, cytokine release syndrome, and heart disease formulations.

Sentiment

Score: 3

Explanation: The sentiment is predominantly negative due to the explicit 'going concern' warning, critically low cash balance, worsening working capital deficit, and multiple defaulted debt obligations. While the company achieved its first revenue and reduced operating losses, these positives are overshadowed by severe financial distress and reliance on uncertain future financing.

Positives

• Achieved first revenue of $97,235 from a new licensing agreement with EndoPure Life Sciences, LLC for the three and nine months ended December 31, 2024.
• Significantly reduced general and administrative expenses by $70,181 (three months) and $474,868 (nine months) compared to the prior year periods, reflecting efforts to minimize costs.
• Improved loss from operations to $(66,591) for the three months and $(478,518) for the nine months ended December 31, 2024, a substantial reduction from prior year losses.
• Net loss decreased to $(100,355) for the three months and $(575,899) for the nine months ended December 31, 2024, indicating improved financial performance.
• Reduced cash used in operating activities to $(253,975) for the nine months ended December 31, 2024, compared to $(723,230) in the prior year, indicating a slower cash burn rate.
• Expanded intellectual property portfolio with new foreign patents issued for Parkinson's disease in China and Japan, and for Mast Cell Activation Syndrome in Israel, Australia, and Japan.
• Received U.S. Patent Application No. 16/878,295 allowance for Myrcene-Containing Complex Mixtures for cardiac hypertrophy, overactive bladder, and refractory chronic cough.
• Positive preclinical results were reported for cannabinoid-based therapy for Parkinson's disease (dose response study), chronic pain, anxiety/depression, cytokine release syndrome, and heart disease formulations.

Negatives

• Substantial doubt exists about the company's ability to continue as a going concern for the next twelve months due to sustained net losses and a significant accumulated deficit.
• Accumulated deficit increased to $(110,642,891) at December 31, 2024, from $(110,066,992) at March 31, 2024.
• Working capital deficit worsened to $(5,323,014) at December 31, 2024, from $(4,992,115) at March 31, 2024.
• Cash and cash equivalents are critically low at $3,016 as of December 31, 2024.
• Multiple notes payable and convertible notes, including the 0% Note Payable dated October 23, 2017, March and July 2017 Convertible Note Offerings, and December 2020 6% Convertible Notes, are currently in default.
• Total liabilities increased to $5,974,481 at December 31, 2024, from $5,417,557 at March 31, 2024.
• No other income was recorded for the three and nine months ended December 31, 2024, compared to $85,000 and $320,000 respectively in the prior year periods, as the note receivable from the sale of Nevada Subsidiaries was fully impaired.
• Internal controls over financial reporting were deemed not effective due to the lack of an audit committee financial expert on the board and the consolidation of principal executive and financial officer duties in one person.

Risks

• The company's ability to continue as a going concern is dependent on obtaining additional financing or capital sources and achieving profitable operations.
• There is no assurance that the company will be successful in raising the necessary capital for future growth plans, and financing may not be on acceptable terms.
• Inability to raise necessary capital could lead to material changes in the business plan, including delays or abandonment of aspects of the plan.
• The company's preclinical studies and clinical trials are subject to risks including delays, costs, and the need for additional trials for regulatory approval.
• Dependence on third parties (CROs, CMOs, contractor laboratories) for preclinical studies, clinical trials, and manufacturing introduces operational risks.
• Legal and regulatory developments in the United States and foreign countries could affect the design, initiation, timing, continuation, progress, or outcome of clinical trials.
• Results from preclinical studies and earlier clinical trials may not be predictive of future results in ongoing or planned clinical trials.
• Difficulties and expenses are associated with obtaining and maintaining regulatory approval for product candidates.
• The company's ability to obtain and maintain intellectual property protection for its product candidates is crucial.
• Exposure to product liability lawsuits, shareholder class action lawsuits, or other litigation poses a financial risk.
• The company's internal computer and information systems are subject to risks of cyberattacks, malicious intrusion, breakdown, destruction, or loss of data privacy.
• The adequacy of capital reserves and liquidity, including access to additional borrowing capacity, is a significant concern.
• General industry and market conditions, unexpected natural disasters, and health epidemics could adversely affect the business.

Future Outlook

The company intends to move its drug development forward towards clinical trials for its proprietary treatments for chronic pain, stress/anxiety, and cytokine release syndrome therapies after Parkinson's disease, depending on the results of ongoing preclinical studies. The primary focus for the lead Parkinson's disease program is evaluating suitable development partners to assist in preparing cannabinoid-based formulas for a first-in-human clinical trial. Talks with multiple potential licensing partners are ongoing and remain promising. The company expects expenses to increase significantly to grow the business, assuming necessary financing is obtained.

Management Comments

• Management has been able, thus far, to finance the losses through debt financing, a public offering, private placements and obtaining operating funds from stockholders.
• The company is continuing to seek sources of financing.
• Management believes that its current and future plans provide an opportunity to continue as a going concern.
• The company runs a lean drug development program through GBSGB and takes effort to minimize expenses, including personnel, overhead, and fixed capital expenses through strategic partnerships with Universities and Contract Research Organizations (CROs).
• The decrease in general and administrative expenses is attributable to continuing efforts to maintain administrative costs at a minimum and to make the best use of limited resources in advancing research & development of the intellectual property portfolio.

Industry Context

The company operates in the plant-inspired biopharmaceutical research and development sector, focusing on disease-targeted formulations. Its strategy includes targeting large markets like Parkinson's disease (projected to grow to $12.8 billion by 2028) and chronic pain (estimated health burden of $560-$650 billion in the US), while also pursuing rare diseases like Mast Cell Activation Syndrome (MCAS) for potential expedited FDA approval. This dual approach aims to balance large market potential with faster regulatory pathways. The emphasis on plant-based and cannabinoid-containing complex mixtures positions the company within the growing natural medicine and cannabis-derived therapeutics space, seeking safer alternatives to conventional treatments like opioids for chronic pain.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or detailed results to assess the company's performance against global benchmarks. It primarily focuses on internal financial metrics and strategic developments.
• Market size projections for Parkinson's disease ($8.8 billion by 2026 in China, $12.8 billion by 2028 globally) and chronic pain ($560-$650 billion in US) are mentioned, but no direct comparison of the company's market share or competitive positioning within these markets is provided.
• The company's strategy to target rare diseases like MCAS for expedited FDA approval is a recognized industry approach for smaller biopharmaceutical companies to bring therapies to market quicker and more cost-effectively, but specific benchmarks for this strategy are not detailed.

Corporate Governance

Legal Proceedings

• A lawsuit was filed on April 11, 2022, in the Eighth Judicial District Court in Clark County, Nevada, by an individual alleging being shot by a security guard at the Teco Facility in May 2020. GB Sciences, Inc., its former subsidiaries, and the security provider are named as defendants. The company denies liability and believes it may have insurance coverage, but is unable to determine the likelihood or amount of damages at this time.

Related Party Transactions

• As of December 31, 2024, $119,451 was recorded in accounts payable related party, due to an entity controlled by a family member of Mr. John Poss (Chief Executive Officer) for marketing services.
• As of December 31, 2024, $7,634 was owed to Mr. John Poss for expenses incurred in connection with business operations.
• As of December 31, 2024, $3,000 was owed to Dr. Andrea Small Howard (President and Director) for expenses incurred in connection with business operations.
• Dr. Andrea Small-Howard receives a consulting fee of $5,000 per month as compensation for assistance in planning and execution of clinical development under the EndoPure licensing agreement.

Stakeholder Impact

• **Shareholders**: Face significant risk of dilution from potential future equity capital raises. The 'going concern' warning indicates a high risk of value erosion or potential bankruptcy. Existing shares may be impacted by the exercise of warrants at low prices ($0.01).
• **Creditors**: Multiple notes payable and convertible notes are in default, indicating high credit risk and potential for non-payment or restructuring of debt. The company intends to negotiate extensions, which may or may not be favorable.
• **Employees**: The company runs a 'lean drug development program' and minimizes expenses, which could imply limited growth opportunities or job security concerns, though no specific impact is detailed.
• **Customers (Future)**: The company's ability to bring its drug candidates to market is dependent on securing financing and successful clinical trials, which directly impacts potential future patients who could benefit from its therapies.
• **Suppliers/Vendors**: The company has $235,000 in invoiced contracts for projects starting in 2025, indicating future business, but its liquidity issues could pose payment risks to these parties.

Next Steps

• Obtain additional financing or capital sources to meet financing requirements and achieve profitable operations.
• Evaluate suitable development partners for the Parkinson's disease therapeutic program to prepare for a first-in-human clinical trial.
• Move drug development forward towards clinical trials for proprietary treatments for chronic pain, stress/anxiety, and cytokine release syndrome therapies after Parkinson's disease.
• Commence work on projects with vendors totaling approximately $235,000 in 2025.
• Negotiate terms of extension for outstanding notes and accrued interest that are in default.

Key Dates

Recommendation

Despite reporting its first revenue and reducing operating losses, GB Sciences faces severe financial distress, evidenced by a 'substantial doubt' about its ability to continue as a going concern, a critically low cash balance of $3,016, a worsening working capital deficit, and multiple significant debt obligations in default. The company's reliance on future, uncertain capital raises, coupled with material weaknesses in internal controls, presents an extremely high-risk investment profile. The accumulated deficit exceeding $110 million indicates a long path to profitability, if achievable at all. For a seasoned investor, the current financial state suggests a high probability of further value erosion or potential bankruptcy, making it an unfavorable investment.

Keywords

Biopharmaceutical, Plant-based medicine, Cannabis, Parkinson's disease, Chronic pain, Mast Cell Activation Syndrome, Intellectual property, Patents, Drug discovery, Preclinical studies, Licensing agreement, SEC filing, 10-Q, GB Sciences, Going concern, Convertible notes